Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Educational information

This lecture by dr. Lam was part of a CME accredited symposium: Novel concepts and treatments of comorbidities in Heart Failure with Preserved Ejection Fraction held at ESC Heart Failure 2018 in Vienna.

Faculty

Prof. Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr. Lam also works as a cardiologist at the UMC Groningen, The Netherlands. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in HFpEF. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novartis and Novo Nordisk.

View slides of the presentation by dr. Lam.